title: Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.
abstract: Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy.
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Poon
authors.forename: Patricia S
authors.initials: PS
authors.lastname: Fox
authors.forename: Barry I
authors.initials: BI
authors.lastname: Samuels
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Hsu
authors.forename: Alison
authors.initials: A
authors.lastname: Gulbis
authors.forename: Martin
authors.initials: M
authors.lastname: Korbling
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Lynne V
authors.initials: LV
authors.lastname: Abruzzo
authors.forename: Roland L
authors.initials: RL
authors.lastname: Bassett
authors.forename: Issa F
authors.initials: IF
authors.lastname: Khouri
mesh_terms: D000328:Adult; D000368:Aged; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012017:Referral and Consultation / Q000592:standards / Q000706:statistics & numerical data; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
keywords: 17p−; CLL; allogeneic transplant